Bibliography
- Heidelberger C, Chaudhuari NK, Danenberg P, Fluorinated pyrimidines. A new class of tumor inhibitory compounds. Nature 1957;179:663-6
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-44
- Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5FU-based chemotherapy: mutations in the DPD gene and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 2003;8:132-8
- Jackman AL, Boyle ET, Harrap KR. TomudexTM (ZD1694): from concept to care, a programme in rational drug discovery. Invest New Drugs 1996;14(3):305-16
- Editorial. Drug company decision to end cancer trial. Lancet 1999;354:1045
- Jones ML, Hummel S, Bansback N, A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 2001;5(25):1-145. Available from: http://www.hta.ac.uk/project/1198.asp
- Hind D, Tappenden P, Tumur I, The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation (review of NICE Guidance No. 33). Health Technol Assessment 2008;12(15). Available from: http://www.nice.org.uk/nicemedia/pdf/word/TA93Guidance.doc. [Accessed July 2009]
- Saunders MP, Valle JW. Why hasn't the National Institute been ‘NICE’ to patients with colorectal cancer? Brit J Cancer 2002;86:1667-9
- BCCA protocol summary for palliative chemotherapy for metastatic colorectal cancer using raltitrexed in patients with previous 5FU toxicity. Available from: http://www.bccancer.bc.ca/NR/rdonlyres/C0A8933B-3AAD-4EBA-A95C-4552A0A060C9/33904/GIRALT_Protocol_1May09.pdf. [Accessed 13 July 2009]
- Germond C, Maroun J, Zwaal C, Wong S, Gastrointestinal Disease Site Group of Cancer Care Ontario's Program in evidence-based Care. Use of raltitrexed (tomudex) in the management of metastatic colorectal cancer. Practice guideline report #2-17. Filename: pebc2-17f.pdf. Available from: http://www.cancercare.on.ca/search/default.aspx?q=raltitrexed&sortby=Relevance&type=-1,1377-78|0,6-76,6-40484&pg=0 [Accessed 1 July 2009]
- Cassidy J. Thymidylate synthase inhibitors in colorectal cancer. Semin Oncol 2000;27(Suppl 5):83-7
- Judson IR. Tomudex (raltitrexed) development: preclinical, phase I and II studies. AntiCancer Drugs 1997;8(Suppl 2):S5-9
- Gunasekara NS, Faulds D. Raltitrexed: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1998;55(3):423-35
- Clarke SJ, Beale PJ, Rivory LP. Clinical and preclinical pharmacokinetics of raltitrexed. Clin Pharmacokinet 2000;39(5):429-33
- British Columbia Cancer Agency Monograph: raltitrexed. Health professional information. Available from: http://www.bccancer.bc.ca/NR/rdonlyres/7E00CDBE-FCA9-43D2-994E-B3ED7DB5A92F/19519/Raltitrexedmonograph_3Nov06.pdf [Accessed 1 July 2009]
- Electronic medicines compendium. Raltitrexed. Available from: http://emc.medicines.org.uk/medicine/2307/SPC/Tomudex/ [Accessed 1 July 2009]
- Cunningham D, Zalcberg JR, Rath U, Final results of a randomised trial comparing ‘Tomudex’ (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. “Tomudex” Colorectal Cancer Study Group [published erratum appears in Ann Oncol 1997;8(4):407]. Ann Oncol 1996;7(9):961-5
- Mel JR, Feliu J, Camps C, Tomudex (raltitrexed) in elderly patients with advanced colorectal cancer (ACC): an effective palliative treatment. Proc Am Soc Clin Oncol 2000;19:257a
- Facchini T, Genet D, Berdah JF, Raltitrexed (‘Tomudex’) has a manageable toxicity profile in elderly patients with metastatic colorectal cancer: final analysis of a multicentre study. Proc Am Soc Clin Oncol 2000;19:298a
- Holbrook AM, Pereira JA, Labiris R, Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106
- Farrugia DC, Aherne GW, Brunton L, Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies. Clin Cancer Res 2000;6:3646-56
- Pazdur R, Vincent M. Raltitrexed (tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial [abstract 801]. Proc Am Soc Clin Oncol 1997;16:228a
- Cocconi G, Cunningham D, Van Cutsem E, Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high- dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998;16(9):2943-52
- Maughan TS, James RD, Kerr DJ, Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359:1555-63. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673602085148
- Thomas RJ, Williams M, Garcia-Vargas J. Lessons learned from raltitrexed – quality assurance, patient education and intensive supportive drugs to optimise tolerability. Clin Oncol 2003;15:227-32
- Zalcberg J. Overview of the tolerability of tomudex (raltitrexed): collective clinical experience in advanced colorectal cancer. Anticancer Drugs 1997;8(Suppl 2):S17-22
- Ford HER, Cunningham D. Safety of raltitrexed. Lancet 1999;354:1824-5
- Young A, Topham C, Moore J, A patient preference study comparing raltitrexed (‘Tomudex’) and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes. Eur J Cancer 2001;8(3):154-61
- Popov I, Carrato A, Sobrero A, Raltitrexed (Tomudex®) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer 2008;44(15):2204-11
- Sargent DJ, Wieand HS, Haller DG, Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664-70
- Wilson KS, Fitzgerald CA, Barnett JB, Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience. Cancer Invest 2007;25(8):711-4
- Saltz LB, Niedzwiecki D, Hollis D, Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25:3456-61
- Ychou M, Hohenberger W, Thezenas S, A randomized phase III study comparing adjuvant 5FU/folinic acid with FOLFIRI in patients with complete resection of liver metastases from colorectal cancer. Ann Oncol 2009. Available from: http://annonc.oxfordjournals.org/cgi/content/abstract/mdp236 [Accessed 30 June 2009]
- Saltz LB, Cox JV, Blanke C, Irinotecan plus fluorouracil and leucovorin in metastatic colorectal cancer. N Engl J Med 2000;343:905-14. Available from: http://content.nejm.org/cgi/content/abstract/343/13/905
- Wolmark N, Yothers G, O'Connell MJ, A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2009;27(Suppl 18); abstract LBA4
- Saltz LB, Clarke S, Díaz-Rubio E, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-9
- Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Available from: http://content.nejm.org/cgi/content/abstract/350/23/2335
- Van Cutsem E, Cunningham D, Maroun J, Raltitrexed: current status and future directions. Ann Oncol 2002;13:513-22
- Zalcberg J, Cunningham D, Green M, Proc Am Soc Clin Oncol 1995, abstract 494. Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=28&abstractID=7490